Cargando…

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells

The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed...

Descripción completa

Detalles Bibliográficos
Autores principales: Avvakumova, S., Pandolfi, L., Soprano, E., Moretto, L., Bellini, M., Galbiati, E., Rizzuto, M. A., Colombo, M., Allevi, R., Corsi, F., Sánchez Iglesias, A., Prosperi, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419579/
https://www.ncbi.nlm.nih.gov/pubmed/36133537
http://dx.doi.org/10.1039/c9na00241c
_version_ 1784777209207062528
author Avvakumova, S.
Pandolfi, L.
Soprano, E.
Moretto, L.
Bellini, M.
Galbiati, E.
Rizzuto, M. A.
Colombo, M.
Allevi, R.
Corsi, F.
Sánchez Iglesias, A.
Prosperi, D.
author_facet Avvakumova, S.
Pandolfi, L.
Soprano, E.
Moretto, L.
Bellini, M.
Galbiati, E.
Rizzuto, M. A.
Colombo, M.
Allevi, R.
Corsi, F.
Sánchez Iglesias, A.
Prosperi, D.
author_sort Avvakumova, S.
collection PubMed
description The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine.
format Online
Article
Text
id pubmed-9419579
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-94195792022-09-20 Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells Avvakumova, S. Pandolfi, L. Soprano, E. Moretto, L. Bellini, M. Galbiati, E. Rizzuto, M. A. Colombo, M. Allevi, R. Corsi, F. Sánchez Iglesias, A. Prosperi, D. Nanoscale Adv Chemistry The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine. RSC 2019-07-23 /pmc/articles/PMC9419579/ /pubmed/36133537 http://dx.doi.org/10.1039/c9na00241c Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Avvakumova, S.
Pandolfi, L.
Soprano, E.
Moretto, L.
Bellini, M.
Galbiati, E.
Rizzuto, M. A.
Colombo, M.
Allevi, R.
Corsi, F.
Sánchez Iglesias, A.
Prosperi, D.
Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
title Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
title_full Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
title_fullStr Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
title_full_unstemmed Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
title_short Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
title_sort does conjugation strategy matter? cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419579/
https://www.ncbi.nlm.nih.gov/pubmed/36133537
http://dx.doi.org/10.1039/c9na00241c
work_keys_str_mv AT avvakumovas doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT pandolfil doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT sopranoe doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT morettol doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT bellinim doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT galbiatie doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT rizzutoma doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT colombom doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT allevir doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT corsif doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT sancheziglesiasa doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells
AT prosperid doesconjugationstrategymattercetuximabconjugatedgoldnanocagesfortargetingtriplenegativebreastcancercells